Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study.

ABSTRACT:

Introduction

Ribociclib is an orally bioavailable cyclin-dependent kinase 4/6 inhibitor. In combination with aromatase inhibitor letrozole, it has approval for treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. First-line therapy with ribociclib + letrozole significantly improves progression-free survival compared to placebo + letrozole in patients with HR+/HER2- advanced breast cancer. In patients with de novo advanced or metastatic breast cancer, ribociclib was able to provide substantial clinical benefit according to data from the MONALEESA-2 study.

Case presentation

Here, we report the complete clinical response in a postmenopausal patient with de novo, locally advanced, pulmonary metastatic

SUBMITTER: Rudlowski C 

PROVIDER: S-EPMC7383283 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature